| Characteristic | Total n = 46 |
| Demographics: | |
| Age (years) | 51 (14) |
| Female (%) | 37 (80) |
| BMI (kg/m2) | 27.0 (5.9) |
| Disease status: | |
| Disease duration (months) | 60 (36 to 142) |
| Erosive disease (%) | 31 (67) |
| IgM-RF+(%) | 30 (65) |
| Anti-CCP+(%) | 32 (70) |
| DAS28 | 5.4 (1.1) |
| ESR (mm/h) | 19 (11 to 34) |
| CRP (mg/litre) | 7 (4 to 17) |
| Postmenopausal women (%) | 19 (51) |
| Drug treatments: | |
| Previous DMARDs | 4.1 (2.0) |
| Methotrexate (mg/week) | 19.1 (6.9) |
| Prednisone use (%) | 13 (28) |
| Prednisone dose (mg/day) | 7.4 (2.3) |
| Bisphosphonate use (%) | 8 (17) |
| Calcium use (%) | 13 (28) |
| Vitamin D use (%) | 12 (26) |
| Bone mineral density: | |
| Lumbar spine | |
| BMD (g/cm2) | 0.96 (0.15) |
| T-score (SD) | −0.82 (1.32) |
| Z-score (SD) | 0.04 (1.23) |
| Femoral neck | |
| BMD (g/cm2) | 0.80 (0.16) |
| T-score (SD) | −0.75 (1.32) |
| Z-score (SD) | 0.19 (1.19) |
Mean values (SD), median and interquartile range (IQR) or percentages are shown.
BMD, bone mineral density; BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.